首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1917825

器官晶片市场－2026-2031年预测

Organs On Chip Market - Forecast from 2026 to 2031

出版日期: 2026年01月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计器官晶片市场将从 2025 年的 150,319,000 美元成长到 2031 年的 625,390,000 美元，复合年增长率为 26.82%。

器官晶片（OOC）市场是生物技术和生命科学工具领域的前沿细分市场，致力于开发和商业化模拟人体器官结构和功能的微型生物工程系统。器官晶片是一种微流体细胞培养装置，通常大小与U盘相仿，其中包含活体人类细胞，这些细胞的排列旨在模拟特定器官或组织界面的关键生理特征。透过整合动态机械力、流体流动和多细胞结构，这些平台旨在创建比传统静态细胞培养更具预测性的体外人体模型。该市场的主要驱动力是临床前研究中对高精度、与人体相关的数据的追求。

市场扩张的驱动力来自药物研发的迫切需求以及科学和伦理范式的转变。其中一个关键驱动因素是药物发现和开发过程中对更具预测性的模型的需求日益增长。临床试验中候选药物持续高失败率（通常是由于疗效不足或动物模型中未预测到的意外毒性）促使人们迫切奖励更好的临床前工具。晶片上（OOC）平台可望在研发早期阶段提供人类特异性的药理学和毒理学数据，从而降低研发风险。这与日益兴起的个人化医疗密切相关，在个人化医疗中，可以使用患者来源的细胞在晶片上测试反应分层和个人化治疗策略。此外，出于伦理方面的考虑以及减少、优化和替代动物试验（3R原则）的监管压力不断增加，正在加速寻找有效的替代方案，使OOC技术成为科学严谨的候选方案。

市场技术发展轨迹以日益增长的生物复杂性和功能整合为特征。创新正从单一器官晶片朝向互联的多器官系统，或称为「晶片上的人体」平台发展，旨在模拟全身药物吸收、分布、代谢和排泄（ADME）以及器官间的相互作用。同时，技术进步的重点在于透过整合患者来源的诱导性多功能干细胞）、免疫系统成分以及更高级的微生物组相互作用，来提高单一晶片的生理相关性。这种从概念验证到稳健、标准化且可重复的、可用于检测的平台的演变，对于实现更广泛的应用至关重要。

竞争格局和资金筹措呈现出一个充满活力的生态系统，该系统由专业生物技术Start-Ups公司、学术衍生企业以及大型製药企业日益增长的参与组成。合作是主导模式，製药公司通常与OOC（体外检测）开发商建立研究伙伴关係或授权协议，共同检验特定应用平台。技术提供者的成功取决于其能否展现清晰且可量化的价值，例如能否复製已知的人体药物反应、预测临床毒性，或与现有方法相比降低检测时间和成本。建立标准化通讯协定并产生可靠的临床检验数据，对于将探索性研究工具转化为工业研发工作流程的整合组件至关重要。

儘管其具有变革性的潜力，但市场主流化应用仍面临许多障碍。首要挑战在于，如何在微观尺度上忠实地模拟人体器官生理，这涉及技术和生物学上的复杂性。重现复杂的细胞微环境、血管分布以及器官特异性的机械讯号传导，仍然是一项重大的工程和生物学难题。这种复杂性直接导致了第二个主要阻碍因素：高成本。开发和运作先进的器官移植平台需要专用设备、耗材和高技能人员，而且必须透过降低后期失败率来证明投资收益的合理性。最后，要获得监管部门的核准以取代现有的动物模型用于安全药理学研究，需要经历漫长的过程，在获得FDA和EMA等机构的核准之前，需要累积大量且令人信服的证据。

总之，晶片器官市场是一个潜力巨大、创新主导的领域，它融合了生物学、工程学和资料科学。其成长在概念上得到了药物研发领域强劲的经济和伦理驱动力的支持。对于业内人士而言，策略重点应体现在三个方面：透过系统检验黄金标准的临床数据来建立信任；透过可扩展的生产和自动化来降低成本；以及开发使用者友好、标准化的系统，使其能够无缝整合到现有的工业实验室工作流程中。最终衡量成功的标准将是该技术能否提高药物研发的可预测性，从而降低成本、加速研发进程，并为患者提供更安全、更有效的治疗方法。

本报告的主要优势：

深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

历史资料（2021-2025 年）和预测资料（2026-2031 年）
成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
竞争对手定位、策略和市场占有率分析
按业务板块和地区（国家）分類的收入成长和预测分析
公司概况（策略、产品、财务资讯、关键趋势等）

The organs-on-chip (OOC) market represents a frontier segment within biotechnology and life sciences tools, dedicated to the development and commercialization of microscale, bioengineered systems that emulate the structure and function of human organs. An organ-on-a-chip is a microfluidic cell culture device, typically no larger than a computer memory stick, that contains living human cells arranged to replicate key physiological aspects of a specific organ or tissue interface. By incorporating dynamic mechanical forces, fluid flow, and multi-cellular architectures, these platforms aim to create more predictive in vitro human models than traditional static cell cultures. This market is fundamentally driven by the quest for higher-fidelity human-relevant data in preclinical research.

Market expansion is fueled by critical needs within pharmaceutical R&D and a shifting scientific and ethical paradigm. The primary driver is the escalating demand for more predictive models in drug discovery and development. The persistent high failure rate of drug candidates in clinical trials, often due to a lack of efficacy or unforeseen toxicity not predicted by animal models, creates a powerful economic incentive for better preclinical tools. OOC platforms offer the potential to provide human-specific pharmacological and toxicological data earlier in the pipeline, thereby de-risking development. This is closely tied to the growing momentum toward personalized medicine, where patient-derived cells on chips could be used to stratify responders or test individualized treatment strategies. Furthermore, increasing ethical concerns and regulatory pressures to reduce, refine, and replace (3Rs) animal testing are accelerating the search for valid alternative methods, positioning OOC technology as a scientifically rigorous candidate.

The market's technological trajectory is defined by increasing biological complexity and functional integration. Innovation is progressing from single-organ chips toward interconnected multi-organ systems, or "body-on-a-chip" platforms, which aim to model systemic drug absorption, distribution, metabolism, and excretion (ADME) and organ-organ crosstalk. Concurrently, advancements are focused on enhancing the physiological relevance of individual chips through the incorporation of patient-derived iPSCs (induced pluripotent stem cells), immune system components, and more sophisticated microbiome interactions. This evolution from proof-of-concept to robust, standardized, and reproducible assay-ready platforms is central to achieving broader adoption.

The competitive and funding landscape is characterized by a vibrant ecosystem of specialized biotechnology startups, academic research spin-offs, and increasing engagement from large pharmaceutical companies. Collaboration is a dominant model, with pharma entities often forming research partnerships or licensing agreements with OOC developers to co-validate platforms for specific applications. Success for technology providers hinges on demonstrating clear, quantifiable value-such as the ability to replicate known human drug responses, predict clinical toxicity, or reduce assay time and cost compared to existing methods. Establishing standardized protocols and generating robust validation data against clinical outcomes are critical for transitioning from exploratory research tools to integrated components of the industrial R&D workflow.

Despite its transformative potential, the market faces substantial barriers to mainstream adoption. A foremost challenge is the inherent technical and biological complexity of faithfully mimicking human organ physiology in a microscale format. Reproducing the intricate cellular microenvironment, vascularization, and organ-specific mechanical cues remains a significant engineering and biological hurdle. This complexity directly contributes to the second major constraint: high cost. The development and use of advanced OOC platforms involve specialized equipment, consumables, and highly skilled personnel, creating a cost profile that must be justified by a demonstrable return on investment through reduced late-stage attrition. Finally, the path to regulatory acceptance for replacing established animal models in safety pharmacology is lengthy and requires the accumulation of extensive, compelling evidence to gain endorsement from agencies like the FDA and EMA.

In conclusion, the organs-on-chip market is a high-potential, innovation-driven sector at the intersection of biology, engineering, and data science. Its growth is conceptually supported by powerful economic and ethical drivers within pharmaceutical R&D. For industry experts, strategic focus must center on systematically validating these platforms against gold-standard clinical data to build confidence, driving down costs through scalable manufacturing and automation, and developing user-friendly, standardized systems that can be seamlessly integrated into existing industrial lab workflows. The ultimate measure of success will be the technology's proven ability to improve the predictability of drug development, thereby reducing costs, accelerating timelines, and delivering safer, more effective therapies to patients.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Organs on Chip Market Segmentation

By Offering
Products
Services
By Organ Type
Liver
Lungs
Kidney
Heart
Others
By Application
Drug Discovery
Regenerative Medicine
Disease Modeling
Others
By End-User
Pharmaceutical & Biotech Companies
Research & Academic Institutes
Others
By Geography
Americas
USA
Others
Europe Middle East and Africa
Germany
United Kingdom
Others
Asia Pacific
China
Japan
South Korea
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ORGANS ON CHIP MARKET BY OFFERING

5.1. Introduction
5.2. Products
5.3. Services

6. ORGANS ON CHIP MARKET BY ORGAN TYPE

6.1. Introduction
6.2. Liver
6.3. Lungs
6.4. Kidney
6.5. Heart
6.6. Others

7. ORGANS ON CHIP MARKET BY APPLICATION

7.1. Introduction
7.2. Drug Discovery
7.3. Regenerative Medicine
7.4. Disease Modeling
7.5. Others

8. ORGANS ON CHIP MARKET BY END-USER

8.1. Introduction
8.2. Pharmaceutical & Biotech Companies
8.3. Research & Academic Institutes
8.4. Others

9. ORGANS ON CHIP MARKET BY GEOGRAPHY

9.1. Introduction
9.2. Americas
- 9.2.1. USA
- 9.2.2. Others
9.3. Europe Middle East and Africa
- 9.3.1. Germany
- 9.3.2. United Kingdom
- 9.3.3. Others
9.4. Asia Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. South Korea
- 9.4.4. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. CN Bio Innovations Ltd
11.2. Emulate Inc.
11.3. BiomimX S.r.l.
11.4. InSphero
11.5. MIMETAS
11.6. TissUse GmbH.
11.7. Hesperos, Inc.
11.8. AlveoliX

12. APPENDIX

12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key Benefits for the Stakeholders
12.5. Research Methodology
12.6. Abbreviations

02-2729-4219

+886-2-2729-4219

License/价格

器官晶片市场－2026-2031年预测